Evaluation of renal transplantation recipients those who do not use steroid with panel reactive antibody and donor specific antibody

被引:0
|
作者
Tanrisev, Mehmet [1 ]
Ayna, Tulay Kilicaslan [2 ,3 ]
Colak, Hulya [1 ]
Yilmaz, Banu [1 ]
Ersan, Sibel [1 ]
Alp, Alper [4 ]
Tugmen, Cem [5 ]
Sert, Ismail [5 ]
Sevgili, Bahar Engin [6 ]
机构
[1] Izmir Tepecik Training & Res Hosp, Dept Nephrol, Izmir, Turkey
[2] Izmir Katip Celebi Univ, Fac Med, Dept Med Biol, Izmir, Turkey
[3] Izmir Tepecik Training & Res Hosp, Tissue Typing Lab, Izmir, Turkey
[4] Mugla Sitki Kocman Univ, Fac Med, Dept Nephrol, Mugla, Turkey
[5] Izmir Tepecik Training & Res Hosp, Dept Gen Surg, Izmir, Turkey
[6] Dursunbey State Hosp, Dept Internal Med, Balikesir, Turkey
来源
关键词
renal transplantation; corticosteroids; panel reactive antibody; donor specific antibody; HLA ANTIBODIES; MYCOPHENOLATE-MOFETIL; IMMUNOSUPPRESSION; WITHDRAWAL; MULTICENTER; AVOIDANCE; REJECTION; THERAPY;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Steroids are the mainstream drugs of immu-nosuppressive regimen in renal transplantation. They are successfully used on induction, maintenance and rejection treatment. Due to complications caused by steroids, treatments are switched to immunosuppressive agents. Graft dysfunction risk caused by reduced total immunosuppression disturbs clinicians very often. We documented the differences among patients by means of clinical presentation and PRA/DSA levels between patients who are using steroids and patients that were prescribed for steroid-free regimen. Methods: 82 individuals who did not use steroid and 52 patients on steroid treatment were included with similar rates of age, sex, primary renal disease, dialysis type, posttransplant follow-up duration and donor type. Pre and posttransplant PRA, DSA levels, posttransplant and current graft function and comorbidities were evaluated. Results: Individuals who do not use steroids were found to have a lower posttransplant creatinine level and glomerular filtration rate (GFR) compared to steroid users. Posttransplant and current spot urinary protein/creatinine rates were also lower in the steroid-free group. However DM, BKVN and induction therapy rates were higher in the steroid-free group. PRA and DSA levels were similar in both groups. On the other hand, posttransplant PRA-I levels were significantly higher in those with less steroid use time. Conclusions: Although steroid free regimens usually worry the clinicians, they can be preferred in patients with low immunological risk for rejection to avoid its side effects such as uncontrolled diabetes, obesity, musculoskeletal problems and cataracts.
引用
收藏
页码:275 / 281
页数:7
相关论文
共 50 条
  • [1] Evaluation of flow cytometric panel reactive antibody in renal transplant recipients - examination of 238 cases of renal transplantation
    Ishida, H
    Tanabe, K
    Furusawa, M
    Ishizuka, T
    Hayash, T
    Tokumoto, T
    Miyamoto, N
    Shirakawa, H
    Shimmura, H
    Shimizu, T
    Toma, H
    TRANSPLANT INTERNATIONAL, 2005, 18 (02) : 163 - 168
  • [2] RENAL TRANSPLANTATION IN DONOR SPECIFIC ANTIBODY POSITIVE RECIPIENTS: SINGLE CENTER EXPERIENCE
    Keven, Kenan
    Sengul, Sule
    Tutkak, Huseyin
    Yalcin, Funda
    Duman, Turker
    Tuzuner, Acar
    TRANSPLANT INTERNATIONAL, 2011, 24 : 200 - 200
  • [3] Panel Reactive Antibody test (PRA) in renal transplantation
    Hajeer, Ali H.
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2006, 17 (01) : 1 - 4
  • [4] THE IMPORTANCE OF FLOW CYTOMETRIC CROSSMATCH, PANEL REACTIVE ANTIBODY AND SINGLE ANTIGEN BEAD TESTS IN DETECTING DONOR-SPECIFIC ANTIBODY IN RENAL TRANSPLANTATION
    Senol, Ozgur
    Tuna, Sena
    Donmez, Ayhan
    Mir, Sevgi
    HLA, 2017, 89 (06) : 391 - 391
  • [5] TRANSPLANTATION OF DONOR SPECIFIC HLA ANTIBODY POSITIVE, FCXM NEGATIVE RENAL ALLOGRAFT RECIPIENTS.
    Kerman, Ronald H.
    Lappin, Jacqueline A.
    Abraham, Jose B.
    Saltarrelli, Jerome G.
    Van Buren, Charles T.
    Kelley, Esther
    McKissick, Eva
    Acorda, Noriel
    Miller, Kristah
    Woolley, Nicholas
    Eaton, Alfred J.
    Adkins, Craig
    Mitchell, Jenna
    Erice, Phillip
    Rodriguez, Luis
    HUMAN IMMUNOLOGY, 2010, 71 : S37 - S37
  • [6] Transplantation of Donor Specific HLA Antibody Positive, FCXM Negative Renal Allograft Recipients.
    Lappin, Jacqueline
    Abraham, Jose
    Katz, Stephen
    Saltarrelli, Jerome
    Kerman, Ronald
    Van Buren, Charles
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 165 - 166
  • [7] Impact of Pretransplant Panel-Reactive Antibody Level on Renal Graft Survival in Patients With a Negative Crossmatch and No Donor-Specific Antibody
    Jun, K. W.
    Kim, M. H.
    Hwang, J. K.
    Kim, S. D.
    Park, S. C.
    Won, Y. S.
    Moon, I. S.
    Chung, B. H.
    Choi, B. S.
    Yang, C. W.
    Kim, Y. S.
    Kim, J. I.
    TRANSPLANTATION PROCEEDINGS, 2016, 48 (03) : 770 - 772
  • [8] Pretransplant Calculated Panel Reactive Antibody in the Absence of Donor-Specific Antibody and Kidney Allograft Survival
    Lan, James H.
    Kadatz, Matthew
    Chang, Doris T.
    Gill, Jagbir
    Gebel, Howard M.
    Gill, John S.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 16 (02): : 275 - 283
  • [9] Detection of lymphocyte panel reactive antibody (PRA) use in kidney transplantation
    Bai, XW
    Yu, LX
    Xu, J
    Fu, SJ
    LATE GRAFT LOSS, 1997, 28 : 223 - 223
  • [10] Outcomes of renal transplantation in recipients with peak panel reactive antibody >30% under tacrolimus-based immunosuppression
    Basu, Amit
    Falcone, John
    Dvorchik, Igor
    Tan, Henkie P.
    Schonder, Kristine
    Marsh, J. Wallis
    Zeevi, Adriana
    Humar, Abhinav
    Shapiro, Ron
    ANNALS OF TRANSPLANTATION, 2011, 16 (03) : 5 - 13